Clinical trials: Non-Small Cell Carcinoma of Lung
Advanced Solid Tumor, Pancreatic Adenocarcinoma
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in…
- Conditions
- Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05585320
- Testing
- IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
- Where
- 20 sites in United States
- Volunteers
- 209 people
- Sponsor
- Immuneering Corporation
Non-small Cell Lung Cancer
Concurrent Chemo-radiation Form NSCLC to a Individualized MLD
Our group has shown in a modeling study that increasing the radiation dose to pre-specified normal tissue dose constrains could lead to increased TCP with the same NTCP in patients with non-concurrent chemo-radiation.
- Trial name
- BRONC CONC MLD (NCT00572325)
- Where
- Netherlands
- Volunteers
- 180 people
- Sponsor
- Maastricht Radiation Oncology
Lung Cancer, Precancerous Condition
Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Polyphenon E, a substance found in green tea, may keep cancer from forming in current or former smokers with bronchial dysplasia.
- Conditions
- Lung Cancer, Precancerous Condition, Tobacco Use Disorder
- Trial name
- NCT00611650
- Testing
- defined green tea catechin extract
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- British Columbia Cancer Agency
Non-Small Cell Lung Cancer
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy.
- Trial name
- HUDSON (NCT03334617)
- Testing
- Durvalumab, Danvatirsen, Ceralasertib
- Where
- 45 sites in United States, Austria and 6 more
- Volunteers
- 528 people
- Sponsor
- AstraZeneca
Breast Cancer, Lung Cancer
Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer
RATIONALE: Understanding how nausea or vomiting caused by chemotherapy effects a patient's treatment decisions may help doctors plan better cancer treatment and may help patients live more comfortably.
- Conditions
- Breast Cancer, Lung Cancer, Nausea and Vomiting
- Trial name
- NCT00416689
- Testing
- assessment of therapy complications, quality-of-life assessment
- Volunteers
- 99 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non Small Cell Lung Cancer
Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients
The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C.
- Trial name
- NCT05812274
- Testing
- Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Columbia University
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with…
- Trial name
- SKYSCRAPER-06 (NCT04619797)
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- 127 sites in United States, Belgium and 19 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Cachexia; Cancer
Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer
This study aims to evaluate the efficacy of the oral postbiotic preparation JK-5G in improving body weight among patients with non-small-cell lung cancer (NSCLC)-related cachexia.
- Trial name
- NCT07185308
- Testing
- Postbiotics, 2.5 g per dose, three times per day
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lung Cancer, NSCLC Stage IV
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab).
- Conditions
- Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
- Trial name
- Cabatezo-1 (NCT05859217)
- Testing
- Cabozantinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jun Zhang, MD, PhD
Non-Small-Cell Lung Cancer
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03728374
- Testing
- Anlotinib
- Volunteers
- 38 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003235
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 294 people
- Sponsor
- Eastern Cooperative Oncology Group
Non-Small Cell Lung Cancer
Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors
The aim of the COMBINATION trial is to prospectively study the sequential approach of using afatinib combined with a short course of chemotherapy, followed by osimertinib, upon progression and acquisition of a T790M mutation…
- Trial name
- COMBINATION (NCT05298176)
- Testing
- Afatinib, Osimertinib, Carboplatin and Pemetrexed
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Amsterdam UMC, location VUmc
NSCLC Stage III, Ensartinib
Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC
The PACIFIC study established the standard of care for immunotherapy consolidation after chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC).
- Conditions
- NSCLC Stage III, Ensartinib, Chemoradiotherapy, ALK
- Trial name
- NCT07235306
- Testing
- Ensartinib 225mg
- Volunteers
- 45 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00028938
- Testing
- epoetin alfa, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Non-Small Cell Lung Cancer
Clinical Effectiveness of Combining Mindfulness-Based Stress Reduction With Exercise Interventione
This study is to assess the clinical effectiveness of combining Mindfulness-Based Stress Reduction (MBSR) with exercise intervention in improving anxiety, depression, sleep quality, and mood regulation in Chinese patients with…
- Trial name
- NCT06224504
- Testing
- routine health education, psychological nursing, MBSR therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanxi Bethune Hospital
Non Small Cell Lung Cancer
SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
This study is an open, multicenter, phase 2 clinical trial of SPGL008 in combination with SSGJ-706 ± chemotherapy for the treatment of advanced non-small cell lung cancer.
- Trial name
- NCT07874984
- Testing
- SSGJ-706, SPGL008, Chemotherapy
- Volunteers
- 220 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Non-small Cell Lung Cancer
Tarceva. ICORG 08-41
The aim of this study is to determine prospectively the value of a recently identified proteomic signature in identifying those patients with lung cancer, who are likely to benefit from and respond favourably to erlotinib…
- Trial name
- NCT01721252
- Where
- 7 sites in Ireland
- Volunteers
- 200 people
- Sponsor
- Cancer Trials Ireland
Carcinoma, Non-Small-Cell Lung
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
The objectives of this single-arm, open-label trial are to assess the efficacy and safety of afatinib as second line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring a…
- Trial name
- NCT02208843
- Testing
- Afatinib
- Where
- 21 sites in Egypt, Malaysia and 5 more
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose [RP2CD]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents…
- Trial name
- KaRAnaSa (NCT07227025)
- Testing
- Amivantamab, Olomorasib
- Where
- 12 sites in United States, Canada and 3 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Lung Cancer
Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Inserting the gene for p53 into a person's cancer cells may improve the body's ability to fight cancer. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004225
- Testing
- Ad5CMV-p53 gene, radiation therapy
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.